OpGen, Inc. (OPGN): Price and Financial Metrics

OpGen, Inc. (OPGN): $0.14

-0.01 (-3.73%)

POWR Rating

Component Grades













OPGN Stock Summary

  • OPGEN INC's market capitalization of $9,397,238 is ahead of merely 3.34% of US-listed equities.
  • With a year-over-year growth in debt of -37.73%, OPGEN INC's debt growth rate surpasses just 8.29% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OPGN comes in at 66.97% -- higher than that of 97.36% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to OPGEN INC are LODE, SPOK, ITRI, SNCR, and ACIW.
  • Visit OPGN's SEC page to see the company's official filings. To visit the company's web site, go to www.opgen.com.

OPGN Valuation Summary

  • In comparison to the median Healthcare stock, OPGN's price/earnings ratio is 100.85% lower, now standing at -0.2.
  • OPGN's price/sales ratio has moved down 10.2 over the prior 92 months.

Below are key valuation metrics over time for OPGN.

Stock Date P/S P/B P/E EV/EBIT
OPGN 2022-12-02 2.4 0.6 -0.2 -0.4
OPGN 2022-12-01 2.8 0.7 -0.2 -0.5
OPGN 2022-11-30 3.2 0.8 -0.3 -0.5
OPGN 2022-11-29 2.8 0.7 -0.2 -0.5
OPGN 2022-11-28 2.7 0.7 -0.2 -0.5
OPGN 2022-11-25 2.9 0.7 -0.2 -0.5

OPGN Growth Metrics

    Its 5 year revenue growth rate is now at -23.11%.
  • The year over year cash and equivalents growth rate now stands at -22.19%.
  • Its 3 year net cashflow from operations growth rate is now at -82.24%.
OPGN's revenue has moved down $739,223 over the prior 15 months.

The table below shows OPGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.311231 -20.24373 -40.72673
2022-06-30 4.10165 -20.62097 -32.67944
2022-03-31 3.94606 -21.55475 -33.92559
2021-12-31 4.306031 -21.47928 -41.97246
2021-09-30 4.232821 -24.62876 -35.10417
2021-06-30 4.050454 -26.723 -36.72306

OPGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPGN has a Quality Grade of D, ranking ahead of 6.34% of graded US stocks.
  • OPGN's asset turnover comes in at 0.068 -- ranking 75th of 81 Healthcare stocks.
  • PMD, MGLN, and THC are the stocks whose asset turnover ratios are most correlated with OPGN.

The table below shows OPGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.068 0.109 -1.125
2021-03-31 0.082 0.075 -1.281
2020-12-31 0.105 0.087 -1.177
2020-09-30 0.122 0.118 -1.429
2020-06-30 0.158 0.329 -1.982
2020-03-31 0.272 0.457 -3.454

OPGN Price Target

For more insight on analysts targets of OPGN, see our OPGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.5 (Moderate Buy)

OPGN Stock Price Chart Interactive Chart >

Price chart for OPGN

OPGN Price/Volume Stats

Current price $0.14 52-week high $1.47
Prev. close $0.15 52-week low $0.14
Day low $0.14 Volume 836,451
Day high $0.16 Avg. volume 368,834
50-day MA $0.22 Dividend yield N/A
200-day MA $0.49 Market Cap 7.76M

OPGN Latest News Stream

Event/Time News Detail
Loading, please wait...

OPGN Latest Social Stream

Loading social stream, please wait...

View Full OPGN Social Stream

Latest OPGN News From Around the Web

Below are the latest news stories about OPGEN INC that investors may wish to consider to help them evaluate OPGN as an investment opportunity.

OpGen, Inc. (OPGN) Q3 2022 Earnings Call Transcript

OpGen, Inc. (OPGN)

Q3 2022 Earnings Conference Call

November 10, 2022 16:30 ET

Company Participants

Alyssa Factor - Investor Relations Associate, Edison Group

Oliver Schacht - President & Chief Executive Officer

Albert Weber - Chief Financial Officer

Conference Call Participants



Welcome to the OpGen Third Quarter 2022 Earnings Call and Business Update. Today, OpGen management will provide an update on the company's current business and outlook for the future. Following options prepared remarks, there will be a live Q&A Session. As a reminder, this conference call is being recorded today November 10 2022, and all participants are...

SA Transcripts on Seeking Alpha | November 11, 2022

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platformElects Yvonne Schlaeppi as new, independent non-executive director to the boardManagement conference call scheduled for November 10, 2022, at 4:30 p.m. EST ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision

Yahoo | November 10, 2022

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional customer contract for Acuitas AMR Gene Panel signed in Q3 2022 ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that to

Yahoo | October 27, 2022

OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Standard Time to discuss the Company’s financial results and provide an update on business activities. Con

Yahoo | October 27, 2022

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, and BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmac

Yahoo | October 25, 2022

Read More 'OPGN' Stories Here

OPGN Price Returns

1-mo -22.87%
3-mo -65.01%
6-mo -74.47%
1-year -89.86%
3-year -88.03%
5-year -99.88%
YTD -86.00%
2021 -50.98%
2020 80.53%
2019 -95.65%
2018 -72.19%
2017 -83.74%

Continue Researching OPGN

Want to see what other sources are saying about Opgen Inc's financials and stock price? Try the links below:

Opgen Inc (OPGN) Stock Price | Nasdaq
Opgen Inc (OPGN) Stock Quote, History and News - Yahoo Finance
Opgen Inc (OPGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7927 seconds.